



Pfizer Inc.
235 East 42nd St.
New York, NY 10017

June 15, 2017

Dear Healthcare Provider,

This communication is to update you on the supply availability of Norpace CR (disopyramide phosphate extended-release capsules), as reported in May 2017.

We have received FDA approval to manufacture the 100mg and 150mg presentations of Norpace CR at an alternative site. We will immediately have both the 100 mg and 150 mg strength presentations available for drop shipment. Norpace CR 100 mg will be available for drop shipment until 9/15/2017 and Norpace CR 150 mg will be available for drop shipment until 6/15/2018.

With this approval, our manufacturing team is actively working to return to a normal resupply pattern of all strengths. Based on the complex manufacturing process for Norpace CR, we are not anticipating resumption of normal resupply across both presentations until March 2018.

Below is a view into the **CURRENT** supply situation and ordering options with NORPACE CR.

NDC #	Presentation	Availability	Related Information
NDC 0025-2732-31	Norpace CR 100 mg capsules; bottle of 100s	Drop shipment thru 9/15/2017	Please contact your wholesaler to arrange drop shipment
NOT AVAILABLE	Norpace CR 100 mg capsules; bottle of 500s	NOT AVAILABLE -On Backorder-	NOT AVAILABLE
NDC-0025-2742-31	Norpace CR 150 mg capsules; bottle of 100s	Drop shipment thru 6/15/2018	Please contact your wholesaler to arrange drop shipment
NOT AVAILABLE	Norpace CR 150 mg capsules; bottle of 500s	NOT AVAILABLE -On Backorder-	NOT AVAILABLE

Pfizer recognizes the importance of Norpace[®] CR to you and your patients and remains committed to this product. Healthcare providers should use their clinical judgment and expertise to determine treatment options for their patients.

For medical questions on Norpace[®] CR, please contact 1-800-438-1985. The full Prescribing Information for Norpace[®] and Norpace[®] CR can be found at: http://www.pfizer.com/files/products/uspi_norpace.pdf

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

Sincerely,
Pfizer Inc.

[Please see Full Prescribing Information, including BOXED WARNING for Norpace and Norpace[®] CR.](#)

(c) 2017 Pfizer Inc. All rights reserved.